Elizabeth Selvin1,2, Bethany Warren3, Xintong He3, David B Sacks4, Amy K Saenger5. 1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; eselvin@jhu.edu. 2. Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD. 3. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: There is growing interest in fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG) as alternative measures of hyperglycemia, particularly for use in settings where traditional measures (glucose and HbA1c) are problematic or where intermediate (2-4 weeks) glycemic control is of interest. However, reference intervals for these alternative biomarkers are not established. METHODS: We measured fructosamine, glycated albumin, and 1,5-AG in a community-based sample of US black and white adults who participated in the Atherosclerosis Risk in Communities (ARIC) Study. We calculated reference intervals, evaluated demographic differences, and derived cutoffs aligned with current diagnostic cutpoints for HbA1c and fasting glucose. RESULTS: In a healthy reference population of 1799 individuals (mean age, 55 years; 51% women; 15% black), the 2.5 and 97.5 percentiles, respectively, were 194.8 and 258.0 μmol/L for fructosamine, 10.7% and 15.1% for glycated albumin, and 8.4 and 28.7 μg/mL for 1,5-AG. Distributions differed by race, sex, and body mass index. Equivalent concentrations of fructosamine and glycated albumin corresponding to an HbA1c of 6.5% (96.5 percentile) were 270.2 μmol/L and 15.6%, respectively. Equivalent concentrations of fructosamine and glycated albumin corresponding to a fasting glucose of 126 mg/dL (93.9 percentile) were 261.7 μmol/L and 15.0%, respectively. CONCLUSIONS: The reference intervals for these biomarkers should inform their clinical use. Diagnostic cutpoint equivalents for fructosamine and glycated albumin could be useful to identify persons with hyperglycemia in settings where fasting glucose or HbA1c are not available or where the interpretation of these traditional measures is problematic.
BACKGROUND: There is growing interest in fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG) as alternative measures of hyperglycemia, particularly for use in settings where traditional measures (glucose and HbA1c) are problematic or where intermediate (2-4 weeks) glycemic control is of interest. However, reference intervals for these alternative biomarkers are not established. METHODS: We measured fructosamine, glycated albumin, and 1,5-AG in a community-based sample of US black and white adults who participated in the Atherosclerosis Risk in Communities (ARIC) Study. We calculated reference intervals, evaluated demographic differences, and derived cutoffs aligned with current diagnostic cutpoints for HbA1c and fasting glucose. RESULTS: In a healthy reference population of 1799 individuals (mean age, 55 years; 51% women; 15% black), the 2.5 and 97.5 percentiles, respectively, were 194.8 and 258.0 μmol/L for fructosamine, 10.7% and 15.1% for glycated albumin, and 8.4 and 28.7 μg/mL for 1,5-AG. Distributions differed by race, sex, and body mass index. Equivalent concentrations of fructosamine and glycated albumin corresponding to an HbA1c of 6.5% (96.5 percentile) were 270.2 μmol/L and 15.6%, respectively. Equivalent concentrations of fructosamine and glycated albumin corresponding to a fasting glucose of 126 mg/dL (93.9 percentile) were 261.7 μmol/L and 15.0%, respectively. CONCLUSIONS: The reference intervals for these biomarkers should inform their clinical use. Diagnostic cutpoint equivalents for fructosamine and glycated albumin could be useful to identify persons with hyperglycemia in settings where fasting glucose or HbA1c are not available or where the interpretation of these traditional measures is problematic.
Authors: Kathleen M Dungan; John B Buse; Joseph Largay; Mary M Kelly; Eric A Button; Shuhei Kato; Steven Wittlin Journal: Diabetes Care Date: 2006-06 Impact factor: 19.112
Authors: N Furusyo; T Koga; M Ai; S Otokozawa; T Kohzuma; H Ikezaki; E J Schaefer; J Hayashi Journal: Diabetologia Date: 2011-09-27 Impact factor: 10.122
Authors: Man Li; Nisa M Maruthur; Stephanie J Loomis; Maik Pietzner; Kari E North; Hao Mei; Alanna C Morrison; Nele Friedrich; James S Pankow; Matthias Nauck; Eric Boerwinkle; Alexander Teumer; Elizabeth Selvin; Anna Köttgen Journal: Sci Rep Date: 2017-06-06 Impact factor: 4.379
Authors: Hyunju Kim; Olive Tang; Casey M Rebholz; Morgan E Grams; Josef Coresh; Robert H Christenson; Elizabeth Selvin Journal: J Appl Lab Med Date: 2022-06-30
Authors: Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602
Authors: Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; John W McEvoy; Robert Christenson; Elizabeth Selvin Journal: Diabetes Res Clin Pract Date: 2022-01-20 Impact factor: 5.602
Authors: Edith Feskens; Lorraine Brennan; Pierre Dussort; Matthieu Flourakis; Lena M E Lindner; David Mela; Naila Rabbani; Wolfgang Rathmann; Frédérique Respondek; Coen Stehouwer; Stephan Theis; Paul Thornalley; Sophie Vinoy Journal: Adv Nutr Date: 2020-09-01 Impact factor: 8.701
Authors: Ayo P Doumatey; Hermon Feron; Kenneth Ekoru; Jie Zhou; Adebowale Adeyemo; Charles N Rotimi Journal: Diabetes Res Clin Pract Date: 2021-06-11 Impact factor: 8.180